Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Topical Diclofenac Gel Reduces Capecitabine-Related Hand-Foot Syndrome

      June 28, 2023
      By Lindsay Fischer
      Article
      Conferences|ASCO Annual Meeting

      Patients with breast and gastrointestinal cancers reported fewer hand-foot syndrome events following treatment with topical diclofenac gel.

      Treatment with topical diclofenac gel significantly reduced the number of grade 2 or 3 cases of hand-foot syndrome (HFS) among patients with cancer receiving capecitabine, according to findings from the D-TORCH study (CTRI/2021/01/030592; NCT05641246), presented during the 2023 American Society of Clinical Oncology Annual Meeting. Further, patients who received the gel also reported lower incidence rates of any grade HFS events, fewer dose reductions of capecitabine, and better HFS-related quality of life (QOL).

      Overall, 25 patients (9.5%) experienced either grade 2 or worse HFS in the study. In the intervention vs control arms, the rate of grade 2/3 HFS was 3.8% (n = 5) vs 15.0% (n = 20). According to the study authors, this translated to a 75% reduction in the risk of developing grade 2 or 3 HFS (RR, 0.25; 95% CI, 0.10-0.066; P = .003).

      “The trial supports diclofenac gel as the new standard of care to prevent capecitabine-associated HFS,” Atul Batra, MD, DM, associate professor with the department of medical oncology at the All India Institute of Medical sciences, said in a presentation of the data.

      As Batra explained, capecitabine is an anticancer agent that is widely used to treat patients with gastrointestinal and breast cancers. HFS is a common adverse event (AE) associated with capecitabine. The rate of incidence is variable but is reported to be between 25% and 75% of patients. Although HFS is not life-threatening, it can impair QOL and result in dose reductions in approximately 10% to 25% of patients who experience it.

      Celecoxib (Celebrex) is efficacious in this setting; however, there are safety concerns with celecoxib. Therefore, investigators sought to leverage a difference cyclooxygenase-2 (COX-2) inhibitor. Because topical COX inhibitors are widely used to treat osteoarthtiris, and are associated with a well-known safety profile, investigators hypothesized that topical diclofenac, a COX inhibitor, could be useful in this setting.

      The study period lasted from February 2021 to September 2022, and the last patient had their 3 month follow-up on January 2023, with a data-cutoff on March 31, 2023. To participate, patients needed to be at least 18 years or older, have an ECOG performance status (PS) between 0 and 2, have a diagnosis of either breast or gastrointestinal cancer and not be receiving an oral or topical nonsteroidal anti-inflammatory drugs (NSAIDs). They also could not have any known allergy to NSAIDS. The primary study end point was incidence rate of grade 2 or worse HFS. Secondary end points included time to HFS, all grade HFS, patient-reported outcomes, capecitabine dose modifications, and safety. Patients were assessed every 3 weeks for efficacy and safety outcomes.

      Patients who participated in this study who were randomly assigned to the intervention arm were asked to apply 1 fingertip unit (FTU) 1% of topical diclofenac on their hands twice daily.

      The study lasted for 12 weeks, or 4 treatment cycles, or until patients developed grade 2 or worse HFS, or experienced other dose limiting toxicities. Treatment could also be stopped per the treating physician’s discretion.

      The median patient age in both arms was 47 years. Approximately 71% of patients in either arm were female (70.0% vs 72.2%). Most patients had an ECOG PS between 0 and 1 (64.6% vs 60.2%), had received combination therapy (56.9% vs 60.9%) and had received a mean dose of capecitabine of approximately 1881.2 mg/m2 (SD, 186.5). In the doclifenac arm (n = 130), 59.2% of patients had breast cancer and 40.8% had gastrointestinal cancer. In the placebo arm (n = 133), 53.4% vs 46.6% of patients had breast and gastrointestinal malignancies, respectively.

      The findings in favor of diclofenac gel were maintained across the various subgroups. This included sex, with male and female patients have an RR of 0.19 (95% CI, 0.02-1.55) and 0.28 (95% CI, 0.10-0.82), respectively. Patients who received combination therapy demonstrated an RR of 0.33 (95% CI, 0.09-1.15). For those receiving capecitabine as monotherapy, the RR was 0.18 (95% CI, 0.04-0.81).

      Patients with an ECOG PS of 2 receiving diclofenac had an RR of 0.51 (95% CI, 0.17-1.55) vs placebo. Those with an ECOG PS of either 0 or 1 had an RR of 0.09 (95% CI, 0.01-0.65). RR was balanced between those who had breast cancer (RR, 0.25; 95% CI, 0.7-0.86) and those who had gastrointestinal cancer (RR, 0.26; 95% CI, 0.06-1.15).

      The rate of all-grade HFS with placebo vs diclofenac was 18.1% (n = 24) vs 6.1% (n = 8), yielding an absolute risk difference of 11.9% (95% CI, 4.1%-19.6%; P = .002). The rates of grade 1, 2, and 3 HFS, specifically, between the diclofenac and placebo arms was 2.3% (n = 3) vs 3.0% (n = 4), 1.5% (n = 2) vs 9.8% (n =13), and 2.3% (n = 3) vs 5.3% (n = 7).

      In the diclofenac arm, the onset time to HFS was 3 weeks for 1 low-grade event, 6 weeks for 3 low-grade events, and 9 weeks for 4 low-grade events. There were 3 grade 2/3 HFS events that developed at week 6, and 2 grade 2/3 HFS events that developed at week 9. In the placebo arm, the onset time was 3 weeks for 2 events (any grade), 6 weeks for 6 events, 9 weeks for 10 events, and 12 weeks for 6 events. In terms of grade 2/3 events, the time to onset was 3 weeks for 1 patient, 6 weeks for 5 events, 9 weeks for 7 events, and 12 weeks for 7 events.

      The percentage of patients who required a capecitabine dose reduction because of HFS was much lower in the diclofenac arm than with placebo, respectively. The rates of reductions were 3.8% (n = 5) vs 13.5% (n = 18).

      Other contributing factors for dose reductions, in both arms, included mucositis (3.8% vs 7.5%), diarrhea (6.1% vs 6.0%), and myelosuppression (2.3% vs 3.8%).

      The QOL assessments were completed by 100 patients (84.6%) in the diclofenac arm and 106 patients (79.7%) in the placebo. The assessments demonstrated that the mean increase in HFS14 score was 8.7 with placebo vs 2.3 with intervention. Higher scores correlate to worse QOL.

      Batra concluded by noting that the number of events were reported, overall, were less than the investigators anticipated. They hypothesized that the placebo effect may have played a role, they also noted that the mean treatment dose with capecitabine was less than 2000 mg/m2 and that may have contributed.

      Reference

      Santhosh A, Kumar A, Pramanik R, et al. Randomized double-blind, placebo-controlled study of topical diclofenac in prevention of hand-foot syndrome in patients receiving capecitabine. J Clin Oncol. 2023;41(suppl 16):12005. doi:10.1200/JCO.2023.41.16_suppl.12005

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
      Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
      Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
      Image of a woman with white hair in front of an Oncology Nursing News blue background
      Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop
      Image of a woman with a white shirt in front of an Oncology Nursing News branded backdrop
      Image of a woman with glasses wearing a striped blouse and a black sweater in front of an Oncology Nursing News branded backdrop
      Image of Kayle Freeman, DNP, APRN, FNP-C, in a video call with an Oncology Nursing News border around the frame
      Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
      Man in suit standing in front of blue watercolor Oncology Nursing News backdrop
      Related Content

      Image of red blood cells

      Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma

      Ashling Wahner
      April 22nd 2025
      Article

      Heather Santone Talks Barriers to Cancer Care in Older Populations

      Heather Santone Talks Barriers to Cancer Care in Older Populations

      Lindsay Fischer
      September 13th 2023
      Podcast

      Heather Santone breaks down some of the barriers that geriatric patients with cancer face—and how nurse navigators can help them overcome these obstacles.


      Image of blood with leukemia cells present

      Variability Found in PROs, Gene Expression During AML Induction Chemo

      Chris Ryan
      April 21st 2025
      Article

      Gene expression in peripheral blood as well as patient-reported outcomes differed for those with acute myeloid leukemia undergoing induction chemotherapy.


      The Vitals

      Linda Bloom Shares Strategies To Improve Presurgical Communication With Patients Who Have Limited English Proficiency

      Lindsay Fischer
      August 14th 2023
      Podcast

      Linda Bloom, MPA, RN, OCN, highlights how tools such as audio interpretation technology and clear masks can help nurses and patients overcome communication barriers in oncology.


      Image of red blood cells

      Daratumumab Decreased Progression Risk in High-Risk Smoldering MM

      Jax DiEugenio
      April 19th 2025
      Article

      Daratumumab showed a decrease in disease progression or death risk vs active monitoring in patients with high-risk smoldering multiple myeloma.


      Image of patients of different ages in a waiting room

      Risk Factors Determine Symptom Burden Profiles by Age Group

      Bridget Hoyt
      April 18th 2025
      Article

      Emetogenic chemotherapy regimens and back pain were associated with higher symptom burden in older, vs younger, patients with cancer.

      Related Content

      Image of red blood cells

      Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma

      Ashling Wahner
      April 22nd 2025
      Article

      Heather Santone Talks Barriers to Cancer Care in Older Populations

      Heather Santone Talks Barriers to Cancer Care in Older Populations

      Lindsay Fischer
      September 13th 2023
      Podcast

      Heather Santone breaks down some of the barriers that geriatric patients with cancer face—and how nurse navigators can help them overcome these obstacles.


      Image of blood with leukemia cells present

      Variability Found in PROs, Gene Expression During AML Induction Chemo

      Chris Ryan
      April 21st 2025
      Article

      Gene expression in peripheral blood as well as patient-reported outcomes differed for those with acute myeloid leukemia undergoing induction chemotherapy.


      The Vitals

      Linda Bloom Shares Strategies To Improve Presurgical Communication With Patients Who Have Limited English Proficiency

      Lindsay Fischer
      August 14th 2023
      Podcast

      Linda Bloom, MPA, RN, OCN, highlights how tools such as audio interpretation technology and clear masks can help nurses and patients overcome communication barriers in oncology.


      Image of red blood cells

      Daratumumab Decreased Progression Risk in High-Risk Smoldering MM

      Jax DiEugenio
      April 19th 2025
      Article

      Daratumumab showed a decrease in disease progression or death risk vs active monitoring in patients with high-risk smoldering multiple myeloma.


      Image of patients of different ages in a waiting room

      Risk Factors Determine Symptom Burden Profiles by Age Group

      Bridget Hoyt
      April 18th 2025
      Article

      Emetogenic chemotherapy regimens and back pain were associated with higher symptom burden in older, vs younger, patients with cancer.

      Latest Conference Coverage

      Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma

      Acupuncture Use in BC Predicted by Social Determinants of Health

      Variability Found in PROs, Gene Expression During AML Induction Chemo

      Blinatumomab-Linked ICANS Cases Higher Than Previously Reported

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.